Robert Niebergall, MD
Internal Medicine · Broken Arrow, OKNPI 1912975012
Payments from drug & device makers
Across 87 payments — averaging $15.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$192
- AstraZeneca$179
- Astellas Pharma US Inc$139
- Novartis$113
- Pfizer$107
- Amarin Pharma, Inc.$84
- plus $494 from 15 others
What the payments were for
- Food & beverage$1,302100%
- Education$60%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 11 | $192 |
| AstraZeneca | 10 | $179 |
| Astellas Pharma US Inc | 10 | $139 |
| Novartis | 6 | $113 |
| Pfizer | 9 | $107 |
| Amarin Pharma, Inc. | 5 | $84 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $77 |
| Kowa Pharmaceuticals America, Inc. | 4 | $59 |
| Merck | 4 | $47 |
| Aytu Biopharma, Inc. | 3 | $41 |
| Boehringer Ingelheim | 3 | $39 |
| Johnson & Johnson | 2 | $37 |
| Lilly USA, LLC | 3 | $36 |
| Arbor Pharmaceuticals, Inc. | 3 | $34 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $27 |
| Amgen | 1 | $20 |
| OPKO Pharmaceuticals, LLC | 1 | $20 |
| Sanofi-aventis U.S. LLC | 1 | $16 |
| GSK | 1 | $14 |
| Shire North American Group Inc | 1 | $14 |
| Avanir Pharmaceuticals, Inc. | 1 | $13 |
How this compares
$1,308 in reported general payments places this provider in the 70th percentile of 840 internal medicine providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 63 | $98,050 |
| EliquisApixaban | 124 | $97,245 |
| FarxigaDapagliflozin Propanediol | 95 | $81,251 |
| OzempicSemaglutide | 53 | $64,205 |
| XareltoRivaroxaban | 59 | $49,017 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 11 | $42,917 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 104 | $39,039 |
| JanuviaSitagliptin Phosphate | 32 | $37,959 |
| JardianceEmpagliflozin | 40 | $37,512 |
| MounjaroTirzepatide | 26 | $36,076 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 62 | $32,542 |
| LinzessLinaclotide | 30 | $26,135 |
| OxycontinOxycodone Hcl | 12 | $22,953 |
| Tresiba Flextouch U-200Insulin Degludec | 21 | $17,835 |
| MyrbetriqMirabegron | 18 | $15,911 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $36 | $134,12689 claims |
| PfizerEliquis | $107 | $97,245124 claims |
| AstraZenecaFarxiga, Symbicort | $179 | $86,075108 claims |
| Novo NordiskOzempic | $192 | $64,20553 claims |
| Johnson & JohnsonXarelto | $37 | $49,01759 claims |
| MerckJanuvia | $47 | $37,95932 claims |
| Boehringer IngelheimJardiance | $39 | $37,51240 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $14 | $25,36837 claims |
| Astellas Pharma US IncMyrbetriq | $139 | $15,91118 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 840 internal medicine providers in Oklahoma.
Other internal medicine in Broken Arrow
- Ranilo VasquezBroken Arrow$15K
- Riley HillBroken Arrow$14K
- Rim TabbaaBroken Arrow$12K
- Al-Ola AbdallahTulsa$10.1M
- Melita TateTulsa$9.1M
- Sagila GeorgeOklahoma City$1.8M
- Ryan MorganOklahoma City$775K
- Renae MayerTulsa$766K
- George FreemanIdabel$742K
- Elise WiesnerNorman$584K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.